Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 152Breast Neoplasms 40Prostatic Neoplasms 31Insulin Resistance 30Obesity 23Neoplasms 16Endometrial Neoplasms 15Pancreatic Neoplasms 14Infertility 14Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 12Anovulation 10Lung Neoplasms 9Neoplasm Metastasis 8Hyperandrogenism 8Glioblastoma 8Diabetes Mellitus 8Squamous Cell Carcinoma of Head and Neck 7Metabolic Syndrome 7Melanoma 7Rectal Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Head and Neck Neoplasms 5Diabetes Mellitus, Type 2 5Brain Neoplasms 5Adenocarcinoma 5Weight Loss 4Uterine Cervical Neoplasms 4

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡